Atossa Therapeutics Inc (ATOS) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Atossa Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Atossa Therapeutics Inc's ROI in the second quarter of 2026?
Atossa Therapeutics Inc recorded a cumulative net loss of $-38 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -102.99%.
Within the Healthcare sector 349 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3786 to 3934.
In a dynamic and often challenging landscape for biopharmaceutical innovation, Atossa Therapeutics, Inc. (Nasdaq: ATOS) continues to establish itself as a vanguard in the fight against breast cancer. The Seattle-based company, dedicated to the prevention and treatment of this prevalent malignancy, recently navigated a significant hurdle in the realm of intellectual property while simultaneously advancing promising therapeutic strategies.On January 30, 2025, Atossa Therapeutics responded to a pivotal ruling from the Patent Trial and Appeal Board (PTAB) regarding U.S. Patent No. 11,572,334, or the 334 patent. The final written decision in case PGR2023-00043 emerges from ongoing efforts to protect proprietary technologies essential for the development of their innovative therapies. This strategic move is not only integral to bolstering Atossa s competitive position but also underlines the importance of intellectual property in fostering long-term growth and sustainability in the biopharmaceutical sector.
In a significant development for breast cancer awareness and early detection, the U.S. Food and Drug Administration (FDA) has implemented a final rule mandating patient notifications regarding breast density as part of updated mammography regulations. This move is hailed as a milestone in addressing a crucial risk factor for breast cancer, potentially leading to earlier diagnosis and better outcomes for patients. The rule s effective date aligns with heightened attention on breast density, a known factor that can obscure cancer detection on mammograms and complicate screening efforts. Atossa Therapeutics Inc. a biopharmaceutical company focused on innovative treatments in the field of breast health, has enthusiastically announced its support for this FDA initiative. The implementation of the new regulation underscores the importance of transparent communication to patients regarding their breast density, which could play a pivotal role in breast cancer prevention strategies. Atossa’s advocacy is consistent with its mission to improve breast cancer outcomes through enhanced early detection and education.
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company, announced on March 18, 2024, that it has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). This comes after receiving written notice on March 15, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq). The company s focus lies in developing innovative medicines in areas of significant unmet medical need in oncology, particularly in using (Z)-endoxifen to prevent and treat breast cancer. In the preceding 12 months ending in the third quarter of 2023, Atossa Therapeutics Inc reported a cumulative net loss of $-30 million, resulting in a negative return on investment (ROI) of -27.47%.
In our rapidly advancing world of medical research and development, cancer remains one of the most formidable challenges, particularly breast cancer, which continues to affect millions of women worldwide. However, in an era of groundbreaking advancements, pharmaceutical company Atossa Therapeutics, Inc. (Nasdaq: ATOS) is taking great strides in pioneering innovative medicines to combat breast cancer and address unmet medical needs. With an unwavering focus on oncology, Atossa Therapeutics is poised to redefine the landscape of breast cancer treatment. Under the astute leadership of President and Chief Executive Officer Dr. Steven Quay, Atossa Therapeutics has made significant progress in the field of biopharmaceuticals. Dr. Quay, renowned for his expertise in translational and personalized medicine, has been at the forefront of leading the company s groundbreaking research and development efforts.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
